MCMedicalCodingSoftware
J3371

J3371: Injection, vancomycin hcl (mylan), not therapeutically equivalent to j3370, 500 mg

HCPCSTerminatedBETOS O1E

J3371 is a HCPCS Level II code for injection, vancomycin hcl (mylan), not therapeutically equivalent to j3370, 500 mg. It belongs to the Drugs Administered Other Than Oral Method section. It was terminated on June 30, 2025 and is not valid on new claims.

This code has been terminated

CMS terminated J3371 on June 30, 2025. It stays in the file as history: a claim you are auditing from before that date may legitimately carry it, but it must not appear on a new claim. The adjacent codes below are the usual place to look for its replacement.

Medicare coverage: Special coverage instructions apply

There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.

From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q4-Oct. This states Medicare’s position on the code, not on your particular claim.

The CMS record for J3371

Long descriptor
Injection, vancomycin hcl (mylan), not therapeutically equivalent to j3370, 500 mg

The official wording. This is what the code means.

Short descriptor
Inj, vancomycin hcl (mylan)

CMS's 28-character form, which is what shows up on a remittance advice.

Added
January 1, 2023

When CMS introduced the code.

Terminated
June 30, 2025

When CMS retired it.

BETOS
O1E

Berenson-Eggers Type of Service: CMS's own analytic grouping.

Pricing indicator
51: Other

Drugs.

Codes adjacent to J3371

HCPCS has no hierarchy: related items simply sit next to each other in the numbering. If J3371 is not quite right, the correct code is very often within a few positions of it.

  • J3350Injection, urea, up to 40 gm
  • J3355Injection, urofollitropin, 75 iuterminated
  • J3357Ustekinumab, for subcutaneous injection, 1 mg
  • J3358Ustekinumab, for intravenous injection, 1 mg
  • J3360Injection, diazepam, up to 5 mg
  • J3364Injection, urokinase, 5000 iu vialterminated
  • J3365Injection, iv, urokinase, 250,000 i.u. vialterminated
  • J3370Injection, vancomycin hcl, 500 mgterminated
  • J3372Injection, vancomycin hcl (xellia), not therapeutically equivalent to j3370, 500 mgterminated
  • J3373Injection, vancomycin hydrochloride, 10 mg
  • J3374Injection, vancomycin hydrochloride (mylan) not therapeutically equivalent to j3373, 10 mg
  • J3375Injection, vancomycin hydrochloride (tyzavan), not therapeutically equivalent to j3373, 10 mg
  • J3376Injection, vancomycin hcl (hikma), not therapeutically equivalent to j3373, 10 mg
  • J3379Injection, valproate sodium, 5 mg
  • J3380Injection, vedolizumab, intravenous, 1 mg
  • J3385Injection, velaglucerase alfa, 100 units
HCPCS Level II2026Q4-Oct· effective October 1, 2026